Jim Cramer's 'Mad Money' Recap: Next Week's Game Plan

Tickers in this article: AAPL AMZN AWAY BNNY CLF CSCO CTRX CVRR CVS DE DIS EBAY ECOM GOOGLGF GS LNG MCK MDLZ MPC PEP PXD STJ SWI TRIP VFC WFM WWAV WYN

Search Jim Cramer's "Mad Money" trading recommendations using our exclusive "Mad Money" Stock Screener.


NEW YORK (TheStreet) -- The markets have something for everyone, Jim Cramer said on "Mad Money"  Friday as he laid out his game plan for next week's trading. Now that the big, bad employment number is behind us, investors are piling into all sorts of stocks, from growth and high-yielders to cyclicals and housing, Cramer said.

That's why on Monday Cramer said he'll be looking out for Annie's , a play on natural foods, and Pioneer Natural Resources , which is sitting atop one of the world's largest oil fields.

On Tuesday Cramer said investors need to keep their eyes on the Goldman Sachs technology conference, which runs through Thursday. Also on the watch list: CVS Caremark , which recently booted tobacco from its stores, and Trip Advisor , a stock Cramer said has run big ahead of earnings.

Cramer dubbed Wednesday "disappointment day," with earnings from John Deere , Cisco and Mondelez . The only bright spot will be Whole Foods Markets , said Cramer, which is poised to snap higher.

On Thursday, it's Pepsico reporting, a stock Cramer said is an opportunity after having fallen hard. He urged caution with WhiteWave Foods , but said activist investors in Cliffs Natural Resources will be good for investors.

Finally, on Friday, VF Corp will answer the question of how well its North Face brand sold during the record cold temperatures across much of the country.

Executive Decision: Daniel Starks

For his "Executive Decision" segment, Cramer once again sat down with Daniel Starks, chairman and CEO of St. Jude Medical , a stock that was up 72% last year and hasn't given up any of its gains so far this year. St. Jude just posted a penny-a-share earnings beat on in-line revenue and guidance.

Starks showed off his company's new, revolutionary pacemaker, currently in clinical testing. The device, which is a fraction of the size of current pacemakers, can be implanted through a non-invasive procedure in as little as eight minutes, and the unit will last for up to 19 years. Starks said that in his opinion, once the device is available there will simply be no reason to choose anything else.